Effects of enoxaparin and nadroparin on major XXXX in high-risk @entity1459 treated with a glycoprotein IIb/IIIa inhibitor.

@entity1 @entity1187 @entity64 @entity11270 @entity1459 @entity951 @entity1427 @entity299 @entity583 @entity204 @entity2120
Clinical trials have reported the beneficial effects of platelet glycoprotein (GP) IIb/IIIa receptor antagonists and low-molecular-weight heparins (LMWH) on major @entity299 (MACE) in @entity1 presenting with @entity1459 or @entity583 . A number of studies have documented the significant superiority of low-molecular-weight heparins, especially enoxaparin, over unfractionated heparin in the treatment of @entity1187 . The purpose of this study was to compare the effects of two different LMWHs, enoxaparin and nadroparin, accompanied by platelet @entity1427 /IIIa inhibition on MACE in high-risk @entity1459 . The study was designed as an open-label and observational study. Sixty-eight @entity1 presenting with @entity1459 associated with high-risk criteria were randomly assigned to treatment with enoxaparin plus tirofiban (36 @entity1 , mean age 57 +/- 11) or nadroparin plus tirofiban (32 @entity1 , mean age: 58 +/- 8). In-hospital MACE including @entity583 ( @entity583 ), recurrent @entity951 , @entity204 , @entity64 , and urgent revascularization were compared between the study groups. @entity1 characteristics and durations of LMWH and tirofiban treatments were not different between the study groups. Coronary artery risk factors, except family history (which was observed more frequently in the @entity2120 group, P = 0.02), were also similar. MACE between the enoxaparin and @entity11270 groups including @entity583 (5.5%, 6%), recurrent @entity951 (19%, 12%), @entity204 (0%, 3%), @entity64 (was not observed in either group), urgent revascularization (14%, 12%) and total MACE (19%, 15%) were not different. @entity2120 and nadroparin, accompanied by @entity1427 /IIIa inhibitor therapy, have similar effects on the development of major @entity299 in @entity1 presenting with @entity1459 and high-risk characteristics.
